The VPC's My Precision Oncology Program (MyPOP) is the lead story in the Nov. 22, 2016 issue of Research Insider, the Vancouver Coastal Health Research Institute's newsletter. The article includes an interview with Dr. Kim Chi, Associate Director of Clinical Research at our Centre. Read the full article here (opens in new window).
OncoGenex Pharmaceuticals Inc. has announced positive survival results from the final analysis of the Apatorsen Phase 2 Borealis-2™ trial in metastatic bladder cancer. Apatorsen (OGX-427) was discovered at the VPC and outlicensed to OncoGenex. The full press release is below; click here for the original article on PR Newswire (opens in new window).
May 18, 2016, Vancouver, B.C – BGI, headquartered in China, and the Vancouver Prostate Centre (VPC) signed a memorandum of understanding to bring together advanced and cost effective sequencing, genomics and computing technologies of BGI with the world class translational cancer research and drug development program at the VPC.